Do Neurohormonal Antagonists Improve Outcomes in Diastolic Heart Failure? Insights From Propensity Matched Studies of Medicare-Linked Optimize-HF

Moderator: Michael W. Rich, MD, Professor of Medicine, Washington University School of Medicine
Findings from 4 propensity-matched studies on the long-term association of 4 neurohormonal antagonists, namely, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs), and aldosterone antagonists (AldoAs) in diastolic HF (DHF) patients or HF with preserved ejection fraction (HF-PEF) patients will be presented and discussed.

Study Patients and Methods
Ali Ahmed, MD, MPH, Professor of Medicine, University of Alabama at Birmingham

ACE Inhibitors and Outcomes in Older HF-PEF Patients
Marjan Mujib, MD, MPH, Epidemiologist, Surgery - Section of Vascular Surgery, University of Alabama at Birmingham

Angiotensin Receptor Blockers and Outcomes in Older HF-PEF Patients
Richard M. Allman, MD, Professor and Director, UAB Geriatrics, University of Alabama at Birmingham

Beta-blockers and Outcomes in Older HF-PEF Patients
O. James Ekundayo, MD, DrPH, Epidemiologist, Meharry Medical College

Aldosterone Antagonists and Outcomes in Older HF-PEF Patients
Ali Ahmed, MD, MPH

Discussants
Wilbert S. Aronow, MD, New York Medical College and Jerome L. Fleg, MD, NHLBI